Sana Biotechnology, Inc.

NasdaqGS:SANA Stock Report

Market Cap: US$852.0m

Sana Biotechnology Balance Sheet Health

Financial Health criteria checks 5/6

Sana Biotechnology has a total shareholder equity of $339.6M and total debt of $0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are $618.7M and $279.0M respectively.

Key information

0%

Debt to equity ratio

US$0

Debt

Interest coverage ration/a
CashUS$251.64m
EquityUS$339.65m
Total liabilitiesUS$279.02m
Total assetsUS$618.67m

Recent financial health updates

Recent updates

Sana Biotechnology: Early-Stage Biotech With Promising Allogeneic CAR-T Pipeline

Jul 14

We're Keeping An Eye On Sana Biotechnology's (NASDAQ:SANA) Cash Burn Rate

Jul 12
We're Keeping An Eye On Sana Biotechnology's (NASDAQ:SANA) Cash Burn Rate

Sana Biotechnology: Now In Overbought Territory

Mar 17

Sana Biotechnology's One-And-Done Solution For Diabetes Impresses In NHP Model (Rating Upgrade)

Jan 11

Is Sana Biotechnology (NASDAQ:SANA) In A Good Position To Deliver On Growth Plans?

Dec 30
Is Sana Biotechnology (NASDAQ:SANA) In A Good Position To Deliver On Growth Plans?

Here's Why We're Watching Sana Biotechnology's (NASDAQ:SANA) Cash Burn Situation

Sep 14
Here's Why We're Watching Sana Biotechnology's (NASDAQ:SANA) Cash Burn Situation

Will Sana Biotechnology (NASDAQ:SANA) Spend Its Cash Wisely?

May 26
Will Sana Biotechnology (NASDAQ:SANA) Spend Its Cash Wisely?

We're Keeping An Eye On Sana Biotechnology's (NASDAQ:SANA) Cash Burn Rate

Dec 19
We're Keeping An Eye On Sana Biotechnology's (NASDAQ:SANA) Cash Burn Rate

Here's Why We're Watching Sana Biotechnology's (NASDAQ:SANA) Cash Burn Situation

Sep 03
Here's Why We're Watching Sana Biotechnology's (NASDAQ:SANA) Cash Burn Situation

Sana Biotechnology A Buy For Potential Cancer Therapies

Jun 27

Is Sana Biotechnology (NASDAQ:SANA) In A Good Position To Deliver On Growth Plans?

May 16
Is Sana Biotechnology (NASDAQ:SANA) In A Good Position To Deliver On Growth Plans?

Sana Biotechnology: Exciting Preclinical Science

Feb 12

Is Sana Biotechnology, Inc. (NASDAQ:SANA) Trading At A 38% Discount?

Oct 13
Is Sana Biotechnology, Inc. (NASDAQ:SANA) Trading At A 38% Discount?

Sana Biotechnology: Hypoimmune Cell Therapies

Jul 01

Sana Biotechnology reports Q1 results

May 05

Financial Position Analysis

Short Term Liabilities: SANA's short term assets ($263.5M) exceed its short term liabilities ($50.7M).

Long Term Liabilities: SANA's short term assets ($263.5M) exceed its long term liabilities ($228.3M).


Debt to Equity History and Analysis

Debt Level: SANA is debt free.

Reducing Debt: SANA has no debt compared to 5 years ago when its debt to equity ratio was 15.5%.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: SANA has less than a year of cash runway based on its current free cash flow.

Forecast Cash Runway: SANA has sufficient cash runway for 1 years if free cash flow continues to reduce at historical rates of 19.6% each year.


Discover healthy companies